This product is indicated for the treatment of major depressive disorder.
1. For the treatment of partial seizures (with or without secondary general seizures) in adults and children over 4 years of age.
2. For the treatment of generalized tonic-clonic seizures in adults and adolescents over 16 years of age.
This product is indicated for the treatment of: · Postherpetic neuralgia · Fibromyalgia · Adjunctive therapy for partial onset seizures in adults
For the treatment of schizophrenia. • Adults The efficacy of aripiprazole in the treatment of schizophrenia was established in short-term (4-week and 6-week) controlled trials of adult patients with schizophrenia. Physicians who choose aripiprazole for long-term treatment should periodically reassess the long-term usefulness of the drug for the individual patient. • Adolescents The efficacy of aripiprazole in the treatment of schizophrenia in adolescent patients (13–17 years of age) was established in a 6-week placebo-controlled trial. Physicians who choose aripiprazole for long-term treatment should periodically reassess the long-term usefulness of the drug for the individual patient.
This product is indicated to improve walking ability in adult patients with multiple sclerosis and walking impairment (EDSS score 4–7).
1. Major depressive disorder (MDD) 2. Obsessive-compulsive disorder (OCD) 3. Panic disorder (PD) 4. Posttraumatic stress disorder (PTSD) 5. Social anxiety disorder (SAD) 6. Premenstrual dysphoric disorder (PMDD)
